In fall 2024, xanomeline trospium chloride (XT) was approved by the U.S. Food and Drug Administration for the treatment of ...
Mental health issues are common in people with traumatic brain injury (TBI) and can continue for years. They may be related ...
Cognition Therapeutics (NASDAQ:CGTX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a note issued to investors on Wednesday,Benzinga ...
A new study published in the Journal of Psychopharmacology has revealed that the way caffeine impacts your thinking skills is ...
NFL teams use the test to measure how quickly the brain can process information. But its emergence has not come without ...
Cognition Therapeutics (CGTX) reported a positive outcome of an analysis of masked data from the ongoing ‘MAGNIFY’ Phase 2 trial of zervimesine ...
Cognition Therapeutics also worked with Arjuna Ratnayaka, Ph.D. in the School of Clinical and Experimental Sciences at the University of Southampton to conduct an in vitro study showing the potential ...
To date, the MAGNIFY study ( NCT05893537) has enrolled 100 participants. All participants are completing a final clinic visit in February 2025. Cognition intends to unblind the study at the end of ...
Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the "Company" or "Cognition") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback